Beyondspring Stock News

BeyondSpring Inc. (NASDAQ:BYSI) price on Friday, February 11, fall -4.81% below its previous days close as a downside momentum from buyers pushed the stocks value to $2.97. A look at the stocks price movement, the close in the last trading session was $3.12, moving within a range at $2.945 and $3.145. The beta value (5-Year BeyondSpring Inc.s (BYSI) Volatility Reaches 6.26%: Dont Be Comfortable Read More »

In last trading session, BeyondSpring Inc. (NASDAQ:BYSI) saw 0.32 million shares changing hands with its beta currently measuring 1.09. Company’s recent per share price level of $3.07 trading at $0.08 or 2.68% at ring of the bell on the day assigns it a market valuation of $113.01M. That closing price of BYSI’s stock is at … BeyondSpring Inc. (NASDAQ:BYSI), 8.79% Above Its High, Could Make A Strong Comeback. Read More »

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen, Inc. (NASDAQ: BIIB) shares

BeyondSpring Inc (NASDAQ: BYSI ) plans to reduce its U.S. workforce by 35% , including reassignment of certain personnel to subsidiaries, which is expected to result in cost savings that will extend the cash runway. The reorganization follows the Full story available on Benzinga.com

BeyondSpring Inc (NASDAQ: BYSI) plans to reduce its U.S. workforce by 35%, including reassignment of certain personnel to subsidiaries, which is expected to result in cost savings that will extend t

NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cance

Premarket stocks to watch under $5 gaining steam in the stock market today. The post Top Premarket Penny Stocks To Watch In The Stock Market Today appeared first on Penny Stocks to Buy, Picks, News an

BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 18.97% and 0.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

- Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant re

BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 18.97% and 0.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Premarket stocks to watch under $5 gaining steam in the stock market today. The post Top Premarket Penny Stocks To Watch In The Stock Market Today appeared first on Penny Stocks to Buy, Picks, News an

BeyondSpring Inc (NASDAQ: BYSI ) announced new data highlighting the mechanism of action of plinabulin in preventing chemotherapy-induced neutropenia (CIN) at the American Society of Hematology (ASH) Annual Meeting and Exposition. The comparison was made between cancer patients receiving plinabulin 40 mg Full story available on Benzinga.com

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cance

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the Company or BeyondSpring) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced new data highlighting the mechanism of action of plinabulin in the prevention of chemotherapy-induced neutropenia (CIN) at the 63 rd American Society of Hematology (ASH) Annual Meeting and Exposition, held virtually and in person in Atlanta, Georgia from December 11-14, 2021. The data demonstrate that adding plinabulin to a myelosuppressive regimen rapidly reversed (within 24 hours) neutropenia and leukopenia in the PROTECTIVE-1 and -2 clinical studies by protecting progenitor stem cells in the bone marrow.